1. Scrip
  2. >>Therapy Areas

J&J In Immunology: 'We Plan To Lead The Orals Market'

 
• By Jessica Merrill

Johnson & Johnson’s historical strength in immunology will form the foundation of a renewed push in the field, with novel candidates for indications such as psoriasis, arthritis and inflammatory bowel disease.    

pill box
J&J is developing two oral drugs for immunology indications • Source: Shutterstock

With a long strong heritage in immunology on the strength of blockbuster brands like Remicade (infliximab), Stelara (ustekinumab) and Tremfya (guselkumab), Johnson & Johnson is looking to continue its leadership in categories like psoriasis, psoriatic arthritis and inflammatory bowel disease with the development of new oral medicines.

Key Takeaways
  • J&J updated investors on its immunology pipeline during a business review.
  • Two key assets are oral drugs: a first-in-class oral peptide targeting IL-23 and an oral small molecule IL-17 inhibitor.
  • JNJ-2113, the IL-23 inhibitor, is in Phase III development for psoriasis and has $5bn in peak sales potential

The company outlined plans to develop two novel oral drugs in immunology, a first-in-class oral peptide targeting IL-23, JNJ-2113, and an oral small-molecule IL-17

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.